Piramal Pharma gains after receiving EIR for Turbhe facility from USFDA

According to the company's exchange filing, the US FDA conducted a general Good Manufacturing Practices (GMP) inspection at the Turbhe facility from 11 February to 17 February 2025. Following the inspection, the US FDA has issued an EIR with a classification of voluntary action indicated (VAI). The receipt of the EIR signifies the successful closure of the inspection.

Piramal Pharma (PPL) offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization; Piramal Critical Care (PCC), a Complex Hospital Generics business; and the India Consumer Healthcare business, selling over-the-counter products.

The pharmaceutical company's consolidated net profit tumbled 63.6% to Rs 3.68 crore despite a 12.54% increase in revenue from operations to Rs 2,204.22 crore in Q3 FY25 over Q3 FY24.